RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+9.33%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$5.05B
AUM Growth
+$5.05B
(+10%)
Cap. Flow
+$474M
Cap. Flow
% of AUM
9.39%
Top 10 Holdings %
Top 10 Hldgs %
27.44%
Holding
165
New
13
Increased
67
Reduced
10
Closed
9
Top Buys
| 1 |
Agilon Health
AGL
|
$284M |
| 2 |
LENZ
LENZ Therapeutics
LENZ
|
$66.1M |
| 3 |
VERV
Verve Therapeutics
VERV
|
$58M |
| 4 |
Lifestance Health
LFST
|
$41.8M |
| 5 |
NeueHealth
NEUE
|
$40.8M |
Top Sells
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$100M |
| 2 |
AstraZeneca
AZN
|
$32.3M |
| 3 |
Inspire Medical Systems
INSP
|
$20.7M |
| 4 |
Atea Pharmaceuticals
AVIR
|
$19.4M |
| 5 |
UnitedHealth
UNH
|
$14M |
Sector Composition
| 1 | Healthcare | 94.39% |
| 2 | Consumer Staples | 1.63% |
| 3 | Industrials | 0.72% |
| 4 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NGM
151
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| – | – | -364,800 | Closed | -$10.6M |
|
|
SNCE
152
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| – | – | -206,200 | Closed | -$2.09M |
|
|
FPRX
153
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – | -2,660,822 | Closed | -$100M |
|
154
Apellis Pharmaceuticals
APLS
$3.48B
| – | – | 0 | – | – |
|
|
155
AstraZeneca
AZN
$248B
| – | – | -650,000 | Closed | -$32.3M |
|
156
Baxter International
BAX
$12.7B
| – | – | -140,000 | Closed | -$11.8M |
|
|
CNTB
157
Connect Biopharma
CNTB
$115M
| – | – | -119,114 | Closed | -$2.2M |
|